NL-OMON27856
Recruiting
Not Applicable
A randomised, multicentre, prospective, phase III trial investigating <br>(a) Neoadjuvant hormonal therapy with exemestane for three versus six months<br> and / or <br>(b) The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer.
TEAM II Study Group0 sites2,478 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer, Neoadjuvant hormonal therapy, Aromatase inhibitor, Adjuvant therapy, Bisphosphonates
- Sponsor
- TEAM II Study Group
- Enrollment
- 2478
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Female patients with histologically, by core needle biopsy\-proven, invasive adenocarcinoma of the breast.
Exclusion Criteria
- •1\. M1 disease by clinical examination according to the NABON guideline.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Crohn's DiseaseEUCTR2005-003337-40-BE
Completed
Phase 3
A Study to Evaluate the Comparitive Safety and Efficacy of Recombinant Human Growth Hormone (rhGH) of USV with Eutropin in the Treatment of Pre-pubertal Children (4 to 12 years) with Growth Hormone DeficencyHealth Condition 1: null- Growth hormone deficiency in pre-pubertal children(4 to 12 years).CTRI/2013/09/003957SV Ltd60
Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying of progression or recurrences in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-GBovartis Pharmaceuticals UK Ltd446
Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung cancerPrevention of bone metastasis in patients with non small cell lung cancer Stage III.MedDRA version: 6.1Level: PTClassification code 10029519EUCTR2004-001101-10-ITOVARTIS FARMA
Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerEUCTR2004-001101-10-HUovartis Pharma Services AG446